These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18045192)

  • 1. Valproic acid as anti-cancer drug.
    Michaelis M; Doerr HW; Cinatl J
    Curr Pharm Des; 2007; 13(33):3378-93. PubMed ID: 18045192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function studies for the panacea, valproic acid.
    Terbach N; Williams RS
    Biochem Soc Trans; 2009 Oct; 37(Pt 5):1126-32. PubMed ID: 19754465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives of valproic acid in clinical practice.
    Činčárová L; Zdráhal Z; Fajkus J
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1535-47. PubMed ID: 24160174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?
    Isoherranen N; Yagen B; Bialer M
    Curr Opin Neurol; 2003 Apr; 16(2):203-11. PubMed ID: 12644750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature.
    Nasrallah HA; Ketter TA; Kalali AH
    J Affect Disord; 2006 Oct; 95(1-3):69-78. PubMed ID: 16780960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
    Duenas-Gonzalez A; Candelaria M; Perez-Plascencia C; Perez-Cardenas E; de la Cruz-Hernandez E; Herrera LA
    Cancer Treat Rev; 2008 May; 34(3):206-22. PubMed ID: 18226465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?
    Haymond J; Ensom MH
    Ther Drug Monit; 2010 Feb; 32(1):19-29. PubMed ID: 19901867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
    Hoffmann K; Czapp M; Löscher W
    Epilepsy Res; 2008 Oct; 81(2-3):107-13. PubMed ID: 18538545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.
    Blaheta RA; Michaelis M; Driever PH; Cinatl J
    Med Res Rev; 2005 Jul; 25(4):383-97. PubMed ID: 15637697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teratology of valproic acid: an updated review of the possible mediating mechanisms.
    Ponzano A; Tiboni GM
    Minerva Ginecol; 2018 Jun; 70(3):303-322. PubMed ID: 28398022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
    Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
    Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic Acid: second generation.
    Bialer M; Yagen B
    Neurotherapeutics; 2007 Jan; 4(1):130-7. PubMed ID: 17199028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of valproic acid on the outcome of glioblastoma multiforme.
    Tsai HC; Wei KC; Tsai CN; Huang YC; Chen PY; Chen SM; Lu YJ; Lee ST
    Br J Neurosurg; 2012 Jun; 26(3):347-54. PubMed ID: 22168970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid exposure leads to upregulation and increased promoter histone acetylation of sepiapterin reductase in a serotonergic cell line.
    Balasubramanian D; Deng AX; Doudney K; Hampton MB; Kennedy MA
    Neuropharmacology; 2015 Dec; 99():79-88. PubMed ID: 26151765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.
    Berendsen S; Broekman M; Seute T; Snijders T; van Es C; de Vos F; Regli L; Robe P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1391-415. PubMed ID: 22668241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
    Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
    J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Determination of Valproic Acid and Its Major Metabolites by UHPLC-MS/MS in Chinese Patients: Application to Therapeutic Drug Monitoring.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    J Chromatogr Sci; 2017 Apr; 55(4):436-444. PubMed ID: 27993840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
    Eikel D; Lampen A; Nau H
    Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of divalproate in all forms of mania and the broader bipolar spectrum: many questions, few answers.
    Bowden C
    J Affect Disord; 2004 Apr; 79 Suppl 1():S9-14. PubMed ID: 15121342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.